Voyager Therapeutics (VYGR) Net Income towards Common Stockholders (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 9.94% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$116.6 million (down 37.72% YoY), and the FY2025 full-year result was -$119.7 million, down 84.18% from the prior year.
• Net Income towards Common Stockholders fell to -$27.9 million in Q1 2026, from -$27.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $124.0 million in Q1 2023 to a low of -$34.5 million in Q4 2024.
• A 5-year average of -$7.5 million and a median of -$22.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 513.84% in 2022 and soared 681.85% in 2023, its largest moves.
• Tracing VYGR's Net Income towards Common Stockholders over 5 years: stood at -$23.6 million in 2022, then surged by 338.7% to $56.4 million in 2023, then plunged by 161.15% to -$34.5 million in 2024, then rose by 20.47% to -$27.4 million in 2025, then slipped by 1.86% to -$27.9 million in 2026.
• Business Quant data shows VYGR's Net Income towards Common Stockholders at -$27.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$27.9 million in Q3 2025.